Haemonetics Corp. Reports Financials and Exit Costs
Ticker: HAE · Form: 8-K · Filed: May 8, 2025 · CIK: 313143
| Field | Detail |
|---|---|
| Company | Haemonetics Corp (HAE) |
| Form Type | 8-K |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, restructuring, disclosure
TL;DR
Haemonetics dropped an 8-K detailing financials and exit costs. Check the numbers.
AI Summary
Haemonetics Corp. announced on May 6, 2025, that it is reporting results of operations and financial condition. The company also disclosed costs associated with exit or disposal activities and filed financial statements and exhibits. The filing details the company's financial performance and any restructuring charges.
Why It Matters
This filing provides investors with crucial updates on Haemonetics' financial health and any significant restructuring expenses, impacting future profitability and strategic direction.
Risk Assessment
Risk Level: medium — The filing concerns financial results and potential restructuring costs, which can introduce uncertainty regarding future performance.
Key Players & Entities
- HAEMONETICS CORP (company) — Registrant
- Massachusetts (jurisdiction) — State of incorporation
- 001-14041 (company_id) — SEC File Number
- 04-2882273 (company_id) — IRS Employer Identification No.
- 125 Summer Street Boston, MA 02110 (address) — Principal executive offices
- 781 - 848-7100 (phone_number) — Registrant's telephone number
- May 6, 2025 (date) — Date of earliest event reported
FAQ
What specific financial results are being reported by Haemonetics Corp. in this 8-K?
The filing indicates that Haemonetics Corp. is reporting 'Results of Operations and Financial Condition' as of May 6, 2025.
Does the filing mention any costs related to business restructuring or closures?
Yes, the filing explicitly lists 'Cost Associated with Exit or Disposal Activities' as an item being reported.
What is the primary purpose of this Form 8-K filing for Haemonetics Corp.?
The primary purpose is to report significant events, including results of operations, financial condition, and costs associated with exit or disposal activities, as of May 6, 2025.
Where is Haemonetics Corp. headquartered?
Haemonetics Corp.'s principal executive offices are located at 125 Summer Street, Boston, MA 02110.
What is the SEC file number for Haemonetics Corp.?
The SEC file number for Haemonetics Corp. is 001-14041.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding HAEMONETICS CORP (HAE).